1. Home
  2. STKE vs MDXH Comparison

STKE vs MDXH Comparison

Compare STKE & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sol Strategies Inc.

STKE

Sol Strategies Inc.

SELL

Current Price

$1.31

Market Cap

67.9M

Sector

N/A

ML Signal

SELL

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.21

Market Cap

68.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
STKE
MDXH
Founded
2002
2003
Country
Canada
Belgium
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
67.9M
68.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
STKE
MDXH
Price
$1.31
$0.21
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $1.80
AVG Volume (30 Days)
★ 442.0K
220.4K
Earning Date
01-28-2027
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$5.10
Revenue Next Year
N/A
$13.22
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.85
$0.40
52 Week High
$3.95
$5.33

Technical Indicators

Market Signals
Indicator
STKE
MDXH
Relative Strength Index (RSI) 42.92 20.10
Support Level $1.00 N/A
Resistance Level $1.37 $0.64
Average True Range (ATR) 0.14 0.06
MACD -0.05 -0.02
Stochastic Oscillator 9.02 0.47

Price Performance

Historical Comparison
STKE
MDXH

About STKE Sol Strategies Inc.

Sol Strategies Inc is engaged in investing in blockchain technologies and crypto currencies. Company executes its Investment Objective through three lines of effort: Treasury management: Maintaining a core portfolio of cryptocurrencies for long-term growth, enhanced with risk management strategies to minimize volatility, and generating yield through lending, staking, and liquidity provisioning; Private equity focused on early stage companies in the DeFi and blockchain sectors; and Active investments to generate yield through strategic activities, including Bitcoin mining and stalking and validating Solana.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: